4.7 Review

What made sesquiterpene lactones reach cancer clinical trials?

Journal

DRUG DISCOVERY TODAY
Volume 15, Issue 15-16, Pages 668-678

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2010.06.002

Keywords

-

Funding

  1. United Nations Development Programme [00072156]

Ask authors/readers for more resources

Sesquiterpene lactones (SLs) are plant-derived compounds often used in traditional medicine against inflammation and cancer. This review focuses on the chemical and biological properties of SLs that lead to enhanced anticancer and anti-inflammatory effects. The chemical properties comprise alkylating center reactivity, lipophilicity, and molecular geometry and electronic features. SLs in clinical trials are artemisinin, thapsigargin and parthenolide and many of their synthetic derivatives. These drugs are selective toward tumor and cancer stem cells by targeting specific signaling pathways, which make them lead compounds in cancer clinical trials.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available